Faculty profile

Stephanie Lheureux

ResearcherMedical OncologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Stephanie Lheureux

Researcher

Medical Oncology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
77 publications in the last five years, latest in 2026.
Senior (last) author on 23 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

142

Publications

328

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Ovarian Cancer Aggressiveness Of Care At End-Of-Life Cost-Effectiveness Psychological Health Psychotherapy Randomized Controlled Trial Supportive Care Traumatic Stress

Latest papers

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium
European Journal of Human Genetics · 2026
Refractory ultra-high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti-PD-L1 therapy.
Gynecologic oncology reports · 2026
Factors influencing care for patients with gynecologic malignancies from culturally and linguistically diverse backgrounds: a questionnaire study (iCALD-2).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · senior author

All 142 publications

Latest funding

Evaluating the Effectiveness of CALM-TF: A Psychotherapeutic Intervention to Alleviate Traumatic Stress in Patients with Advanced Ovarian Cancer
CIHR · 2025 · Nominated PI
$952,425
Randomized controlled trial of in-person and virtual Symptom screening with Targeted Early Palliative care (STEP2) in patients with advanced cancer
CIHR · 2023 · Co-investigator
$929,475
Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach
CIHR · 2023 · Principal investigator
$100,000

All 5 grants and awards

142 publications.

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium

Farncombe KM, Sobotka JA, Aronson M, Basik M, Bombard Y, Born L, Cheifetz R, Clausen M, Coburn N, Dawson L

European Journal of Human Genetics20263 citations

DOI: 10.1038/s41431-026-02014-z

Refractory ultra-high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti-PD-L1 therapy.

Venegas L, Grant B, Veneziani AC, Lheureux S, Deljoomanesh S, Millar BA, Bouchard-Fortier G, Jivraj N, Bowering V, Pulman K, Oza AM

Gynecologic oncology reports2026

DOI: 10.1016/j.gore.2026.102137 PMID: 42325811

Factors influencing care for patients with gynecologic malignancies from culturally and linguistically diverse backgrounds: a questionnaire study (iCALD-2).

Kasherman L, Braik D, Gonzalez-Ochoa E, Shukla A, Odujoko O, Lajkosz K, Wang C, Grant R, Dhani N, Bowering V, Croke J, Philp L, Oza A, Lheureux S

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026Senior author

DOI: 10.1007/s00520-026-10881-x PMID: 42307686

Antibody-drug conjugates in gynecologic cancers.

Barquin A, Kasherman L, Lheureux S, Madariaga A

Cancer2026

DOI: 10.1002/cncr.70417 PMID: 42226034

Rethinking ovarian cancer III: the past decade and future directions.

Balkwill FR, Laumont CM, Burdett N, Le Saux O, Garsed DW, Grither WR, Nijhuis AM, Recouvreux MS, Kang Z, Zhang R, Chiappinelli KB, Lee JS, Laniti DD, McNeish I, Ahmed AA, Rottapel R, Conejo-Garcia JR, Odunsi K, Pharoah PDP, Zamarin D, Ishak CA, Fotopoulou C, Buckanovich RJ, Labidi-Galy I, Brenton JD, Lengyel E, Cook DP, George SHL, Lheureux S, Drapkin R, Nephew KP, Adams S, Pathania S, Nelson BH, Färkkilä A, Fuh K, Neel BG, Bowtell DD

Nature reviews. Cancer2026

DOI: 10.1038/s41568-026-00916-0 PMID: 41975230

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial.

Veneziani AC, Lheureux S, Millar DG, Dhani N, Colombo I, Madariaga A, Soberanis Pina P, Atale S, Chan YL, Lee J, Ramsahai J, Quintos J, Wang L, Li X, Bowering V, Ohashi P, Wang B, Oza AM

Nature communications2026

DOI: 10.1038/s41467-026-72125-0 PMID: 42129168

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Herrera M, Marhon SA, Liu ZA, Loo H, Abbas-Aghababazadeh F, Bruce JP, Chen D, Van de Laar E, Chow H, Bedard PL, Abdul Razak AR, Spreafico A, Butler MO, Lheureux S, Pugh TJ, Haibe-Kains B, Siu LL, De Carvalho DD, Spiliopoulou P

Cancer immunology research2026

DOI: 10.1158/2326-6066.cir-26-0365 PMID: 42593482

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Strum S, Murray C, Genta S, Sanz-Garcia E, Razak A, Lheureux S, Pipinikas C, Wang BX, Chevalier A, Smith CG, Spreafico A, Siu LL, Elliott M, Cescon DW

International journal of molecular sciences2026

DOI: 10.3390/ijms27093979 PMID: 42123559

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M, Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP)

JAMA oncology2026

DOI: 10.1001/jamaoncol.2026.1924 PMID: 42348196

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Rosen EY, Yap TA, Fontana E, Lee EK, Mahalingam D, Højgaard M, Mettu NB, Cote GM, Plummer R, Koehler M, Ulanet D, Fei K, Silverman IM, Schonhoft JD, Rimkunas V, Bacque ES, Gomez G, Fretland AJ, Roulston A, Li L, Baruah P, Zimmermann M, Yang J, Carneiro BA, Lheureux S

Clinical cancer research : an official journal of the American Association for Cancer Research2026Senior author

DOI: 10.1158/1078-0432.ccr-25-2240 PMID: 41563386

Something wrong or missing on this profile? Suggest a correction

Stephanie Lheureux

Research

Latest papers

Latest funding

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium

Refractory ultra-high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti-PD-L1 therapy.

Factors influencing care for patients with gynecologic malignancies from culturally and linguistically diverse backgrounds: a questionnaire study (iCALD-2).

Antibody-drug conjugates in gynecologic cancers.

Rethinking ovarian cancer III: the past decade and future directions.

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial.

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Evaluating the Effectiveness of CALM-TF: A Psychotherapeutic Intervention to Alleviate Traumatic Stress in Patients with Advanced Ovarian Cancer

Randomized controlled trial of in-person and virtual Symptom screening with Targeted Early Palliative care (STEP2) in patients with advanced cancer

Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach

Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)

Viral mimicry tolerance as a mechanism of early tumor immune evasion

Frequent collaborators

Lisa Wang

Anna Spreafico

Neesha Dhani

Amit Oza

Xuan Li

Jennifer Croke

Robert Rottapel

Jenny Lau

Stephen Welch

Kathy Han

Enrique Sanz Garcia

Camilla Zimmermann

Breffni Hannon

Wei Xu

Benjamin Haibe-Kains

Tracy Stockley

Robert Grant

Eran Shlomovitz

Holger Hirte

Michael Milosevic

Anne-Marie Mes-Masson

Gary Rodin

Lucy Gilbert

Geoffrey Liu

Allan Covens

Ming-Sound Tsao

Catherine O'Brien

Lisa Avery

Amy Liu

Rahim Moineddin

Gonzalo Sapisochin

Karineh Kazazian

Philippe Bedard

Eitan Amir

Tony Panzarella

Patrick Veit-Haibach